Gilead Sciences
Develops HIV antivirals, liver-disease medicines, and oncology therapies including CAR-T treatments.
$139.30
After-hours close−6.35 (−4.36%)
At close$145.65(−2.16%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $2.15 | — | — |
| Aug 2026 | −$7.25 | −$6.75 | +6.9% |
| Aug 2026 | −$7.25 | −$6.75 | +6.9% |
| May 2026 | $1.91 | $2.03 | +6.3% |
| Feb 2026 | $1.81 | $1.86 | +2.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Oct 2025 | |||
| Aug 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | $2.15 | — | — | $7.78B | — | — |
| Aug 4, 2026 | −$7.25 | −$6.75 | +6.9% | $7.40B | $7.80B | +5.5% |
| Aug 3, 2026 | −$7.25 | −$6.75 | +6.9% | $7.40B | $7.80B | +5.5% |
| May 7, 2026 | $1.91 | $2.03 | +6.3% | $6.91B | $6.96B | +0.7% |
| Feb 10, 2026 | $1.81 | $1.86 | +2.8% | $7.69B | $7.93B | +3.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Oct 30, 2025 | ||||||
| Aug 7, 2025 | ||||||
| Apr 24, 2025 | ||||||
| Feb 11, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 8, 2024 | ||||||
| Apr 25, 2024 | ||||||
| Feb 6, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 3, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Feb 2, 2023 | ||||||
| Oct 27, 2022 | ||||||
| Aug 2, 2022 | ||||||
| Apr 28, 2022 | ||||||
| Feb 1, 2022 | ||||||
| Oct 28, 2021 | ||||||
| Jul 29, 2021 | ||||||
| Apr 29, 2021 | ||||||
| Feb 4, 2021 | ||||||
| Oct 28, 2020 | ||||||
| Jul 30, 2020 | ||||||
| Apr 30, 2020 | ||||||
| Feb 4, 2020 | ||||||
| Oct 24, 2019 | ||||||
| Jul 30, 2019 | ||||||
| May 2, 2019 | ||||||
| Feb 4, 2019 | ||||||
| Oct 25, 2018 | ||||||
| Jul 25, 2018 | ||||||
| May 1, 2018 | ||||||
| Feb 6, 2018 | ||||||
| Oct 26, 2017 | ||||||
| Jul 26, 2017 | ||||||
| May 2, 2017 | ||||||
| Feb 7, 2017 | ||||||
| Nov 1, 2016 | ||||||
| Jul 25, 2016 | ||||||
| Apr 28, 2016 | ||||||
| Feb 2, 2016 | ||||||
| Oct 27, 2015 | ||||||